Clinical Trial Update: Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the biodistribution and pharmacokinetics of the PET radiopharmaceutical 18F-C SNAT4 for cancer, including lung cancer, has been suspe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lung Cancer

Drugs mentioned

• 18F-C SNAT4

Snippet

Sponsor: Stanford University | Conditions: Cancer, Lung Cancer | Phase 1 | Status: SUSPENDED